Sino Biopharmaceutical (HKG:1177) has entered into a global collaboration agreement with Biosion and Aclaris Therapeutics for jointly developed product BSI-045B (TQC2731), a Thursday bourse filing said.
Aclaris Therapeutics has also entered into a license agreement with Biosion for the exclusive rights to develop, manufacture, and commercialize the drug and another preclinical product worldwide, excluding Mainland China, Macau, Hong Kong, and Taiwan.
The deal includes over $40 million in upfront cash and reimbursements, 19.9% of Aclaris' common stock valued at approximately $54 million, potential milestone payments of over $900 million, and a single-digit royalty on annual net sales.
BSI-045B (TQC2731) is currently being evaluated in clinical trials for indications, including asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。